Literature DB >> 16094905

Serum albumin in Down Syndrome with and without Alzheimer's Disease.

C S Clarke1, F J Bannon.   

Abstract

AIMS: We investigated whether or not serum albumin concentrations in Down Syndrome were lower than those of a cohort of similarly moderately- to-severely-disabled institutionalised patients without Down Syndrome and, if so, whether or not this could be ascribed to the presence of liver disease. We also sought to determine the influence of Down Syndrome, age, liver disease, and Alzheimer's Disease on the serum albumin concentration.
METHODS: We performed a cross-sectional study on 205 institutionalised patients with Learning Disabilities (47 with Down Syndrome, 158 without), and used multiple regression techniques to determine the relative effects of age, liver disease, and the presence or absence of Down Syndrome on the serum albumin concentration. Among Down Syndrome patients. We also sought to determine the association between serum albumin concentration and the presence of Dementia of Alzheimer's Type.
RESULTS: Down Syndrome patients had lower serum albumin levels than non-Down Syndrome patients. Serum albumin concentrations declined with age at a similar rate in both groups, such that the effect on serum albumin of having Down Syndrome was equivalent to an additional 44 years of age. The serum albumin concentration in Down Syndrome patients with Alzheimer's Disease was greater than that in Down Syndrome patients without Alzheimer's Disease.
CONCLUSIONS: Down Syndrome is associated with a low serum albumin concentration, independently of the presence of liver disease. The advent of Alzheimer's Disease in Down Syndrome is not associated with a further fall, and may be associated with a rise, in serum albumin concentrations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16094905     DOI: 10.1007/bf03169121

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  19 in total

Review 1.  Use of albumin in the intensive care unit.

Authors:  Marc-Jacques Dubois; Jean-Louis Vincent
Journal:  Curr Opin Crit Care       Date:  2002-08       Impact factor: 3.687

Review 2.  Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests.

Authors:  D R Dufour; J A Lott; F S Nolte; D R Gretch; R S Koff; L B Seeff
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

3.  Serum proteins in Down's syndrome.

Authors:  A T Rundle; J Atkin; B Clothier
Journal:  Dev Med Child Neurol       Date:  1973-12       Impact factor: 5.449

4.  Serum protein fractions in patients with Down's syndrome (mongolism).

Authors:  E L Greene; I R Shenker; S Karelitz
Journal:  Am J Dis Child       Date:  1968-05

5.  Proteins in serum and cerebrospinal fluid in demented patients with Down's syndrome.

Authors:  I Elovaara
Journal:  Acta Neurol Scand       Date:  1984-05       Impact factor: 3.209

Review 6.  Down syndrome--a disruption of homeostasis.

Authors:  B L Shapiro
Journal:  Am J Med Genet       Date:  1983-02

Review 7.  Clinical aspects of Down's syndrome from infancy to adult life.

Authors:  M Tolksdorf; H R Wiedemann
Journal:  Hum Genet Suppl       Date:  1981

8.  The Test for Severe Impairment: an instrument for the assessment of patients with severe cognitive dysfunction.

Authors:  M Albert; C Cohen
Journal:  J Am Geriatr Soc       Date:  1992-05       Impact factor: 5.562

9.  Down's syndrome and hepatitis: an evaluation of carrier status.

Authors:  J L Dicks; E S Dennis
Journal:  J Am Dent Assoc       Date:  1987-05       Impact factor: 3.634

10.  Neuropsychological evaluation of adults with Down's syndrome: patterns of selective impairment in non-demented old adults.

Authors:  J V Haxby
Journal:  J Ment Defic Res       Date:  1989-06
View more
  3 in total

1.  The elevated copper binding strength of amyloid-β aggregates allows the sequestration of copper from albumin: a pathway to accumulation of copper in senile plaques.

Authors:  Dianlu Jiang; Lin Zhang; Gian Paola G Grant; Christopher G Dudzik; Shu Chen; Sveti Patel; Yuanqiang Hao; Glenn L Millhauser; Feimeng Zhou
Journal:  Biochemistry       Date:  2013-01-11       Impact factor: 3.162

2.  Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.

Authors:  Maruan Hijazi; José M Medina; Ana Velasco
Journal:  Mol Neurobiol       Date:  2016-01-23       Impact factor: 5.590

Review 3.  Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?

Authors:  Carmen Martínez-Cué; Renata Bartesaghi
Journal:  Nutrients       Date:  2022-07-13       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.